Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

Conditions:Skin and Soft Tissue Infections, Skin and Soft Tissue Infections
Therapuetic Areas:Dermatology / Plastic Surgery
Age Range:4 - Any
Start Date:March 2019
End Date:August 2020
Contact:Shinwook Kang

Use our guide to learn which trials are right for you!

A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa

The objective of this study is to compare the efficacy and safety of RGN-137 topical gel with
that of placebo gel for treatment of junctional epidermolysis bullosa (JEB) or dystrophic
epidermolysis bullosa (DEB).

RGN-137 will be evaluated for efficacy and safety compared to a Placebo. A matched-pair
design will be used to evaluate RGN-137 treatment versus placebo for treatment of 15 subjects
with JEB or DEB. Eligible subject must have 1 set of matched-pair wound. The investigator
will assign pair of index wounds, each wound with an area between 5cm2 and 50cm2, inclusive,
for the eligible subject on Day 1, and for each pair, one wound will be randomized to receive
RGN-137 gel and the other to receive Placebo gel. Subjects and independent evaluator will be
blinded to the treatment assignments for each wound.

Inclusion Criteria:

- Male or female and at least 4 years old with a diagnosis of DEB or JEB

- Patients and their parents or guardians must be willing and able to provide written
informed consent/assent

- Presence of 1 pair of stable index wounds within the specified size range at study

1. Index wounds must have a surface area between 5 cm2 and 50 cm2, inclusive at the
screening visit

2. The index wounds selected as pairing must be relatively matched in terms of size
and location

- Women of childbearing potential must have a negative pregnancy test prior to

- Sexually active subjects must agree to use medically accepted methods of contraception
during the study

Exclusion Criteria:

- Have any clinical evidence of local infection of the index lesion

- Use of prior or concomitant medication (Any investigational drug within 30 days,
Immunotherapy or cytotoxic chemotherapy within 60 days, Systemic steroidal therapy
within 30 days, and topical steroidal therapy within 14 days)

- History of sensitivity to any component of the treatment

- Neurological, cardiovascular, respiratory, hepatic, renal, or metabolic disease likely
to interfere with the subject's participation in or completion of the study (At the
discretion of investigator, participants with cardiomyopathy can participate)

- Current or former malignancy, including a history of squamous cell carcinomas

- Arterial or venous disorder resulting in ulcerated wounds

- Uncontrolled diabetes mellitus

- Pregnancy or breastfeeding during the study

- Girls or women who have had menarche but have not completed menopause

- Any condition or situation likely to cause the subject to be unable or unwilling to
participate in the study procedures
We found this trial at
San Antonio, Texas 78218
Principal Investigator: John C. Browning, MD
Phone: 210-660-1157
San Antonio, TX
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
Principal Investigator: Anne W Lucky, MD
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
Cincinnati, OH
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
Principal Investigator: Leslie Castelo-Soccio, MD, PhD
Phone: 215-590-0862
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
Philadelphia, PA
Click here to add this to my saved trials
Evanston, Illinois 60208
Principal Investigator: Amy Paller, MD
Evanston, IL
Click here to add this to my saved trials